Organon & Co
NYSE:OGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Organon & Co
Organon & Co
Stock-Based Compensation
Organon & Co
Stock-Based Compensation Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Organon & Co
NYSE:OGN
|
Stock-Based Compensation
$101m
|
CAGR 3-Years
36%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$529m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$640m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$656.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
See Also
What is Organon & Co's Stock-Based Compensation?
Stock-Based Compensation
101m
USD
Based on the financial report for Dec 31, 2023, Organon & Co's Stock-Based Compensation amounts to 101m USD.
What is Organon & Co's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
13%
Over the last year, the Stock-Based Compensation growth was 35%. The average annual Stock-Based Compensation growth rates for Organon & Co have been 36% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
